Puretech's lyt-300 (oral allopregnanolone) demonstrates oral bioavailability, tolerability and gabaa receptor target engagement in healthy volunteers

Boston--( business wire )--puretech health plc (nasdaq: prtc, lse: prtc) ("puretech" or the "company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced topline results from the completed, multi-part phase 1 trial of lyt-300 (oral allopregnanolone).
PRTC Ratings Summary
PRTC Quant Ranking